INT86383

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2000
Last Reported 2010
Negated 1
Speculated 8
Reported most in Body
Documents 258
Total Number 268
Disease Relevance 173.94
Pain Relevance 13.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EGFR) cell morphogenesis (EGFR) Golgi apparatus (EGFR)
endoplasmic reticulum (EGFR) intracellular (EGFR) enzyme binding (EGFR)
Anatomy Link Frequency
lung 11
skin 5
kidney 3
corneal epithelial cell 3
neck 3
EGFR (Homo sapiens)
EGFR - T790M (1)
Pain Link Frequency Relevance Heat
Kinase C 20 100.00 Very High Very High Very High
lidocaine 33 99.98 Very High Very High Very High
Potency 44 99.92 Very High Very High Very High
cINOD 863 98.90 Very High Very High Very High
antagonist 171 98.36 Very High Very High Very High
palliative 142 97.64 Very High Very High Very High
bradykinin 24 97.64 Very High Very High Very High
Inflammation 372 97.52 Very High Very High Very High
Cannabinoid 93 96.72 Very High Very High Very High
Analgesic 28 95.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Weight Loss 32 100.00 Very High Very High Very High
Breast Cancer 2174 99.96 Very High Very High Very High
Cancer 6465 99.92 Very High Very High Very High
Coronary Artery Disease 219 99.92 Very High Very High Very High
Cholangiocarcinoma 537 99.84 Very High Very High Very High
Osteogenic Sarcomas 159 99.84 Very High Very High Very High
Apoptosis 2160 99.82 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 1499 99.80 Very High Very High Very High
Colon Cancer 1220 99.80 Very High Very High Very High
Carcinoma 503 99.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In a recent phase II study of lapatinib, a dual inhibitor of EGFR and HER2, in recurrent/metastatic salivary gland carcinomas, including two MECs, Agulnik et al. demonstrated disease stabilization that lasted for more than 6 months in 36% of the patients; no objective responses were observed.
Negative_regulation (inhibitor) of EGFR in salivary gland associated with carcinoma and disease
1) Confidence 0.59 Published 2008 Journal J Med Case Reports Section Body Doc Link PMC2570365 Disease Relevance 0.73 Pain Relevance 0
Furthermore, there is some evidence to suggest that bevacizumab inhibits the EGFR autocrine function (Petit et al 1997; Hirata et al 2002).
Negative_regulation (inhibits) of EGFR
2) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.65 Pain Relevance 0
There are several methods of EGFR inhibition including monoclonal antibodies directed against the external region and small molecule inhibitors of TK domain.
Negative_regulation (inhibition) of EGFR in external
3) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2721286 Disease Relevance 0.73 Pain Relevance 0
A different method of blocking EGFR is by inhibiting the cytoplasmic TK domain.
Negative_regulation (blocking) of EGFR
4) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.47 Pain Relevance 0
EGFR inhibition can result in follicle occlusion and acneiform eruption with inflammation (Journagan 2006).
Negative_regulation (inhibition) of EGFR in follicle associated with inflammation and acneiform eruptions
5) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.72 Pain Relevance 0.05
Because EGFR is highly expressed in the apical membrane of the loop of Henle, it raises the possibility that blocking EGFR could interfere with magnesium transport in this region of the nephron (Schrag et al 2005).
Negative_regulation (blocking) of EGFR in nephron
6) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721306 Disease Relevance 0.35 Pain Relevance 0.06
Nevertheless, regulation of serum magnesium also depends on gastrointestinal absorption, and an effect of EGFR inhibition on this process cannot be excluded at the present time.


Negative_regulation (inhibition) of EGFR
7) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721306 Disease Relevance 0.39 Pain Relevance 0.08
Development of hypomagnesemia may be related to inhibition of EGFR in the kidneys, although it may also be a consequence of diarrhea (Lenz 2006).
Negative_regulation (inhibition) of EGFR associated with hypomagnesemia and diarrhoea
8) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721306 Disease Relevance 0.53 Pain Relevance 0
Agents capable of inhibiting EGFR activity with resultant inhibition of cell proliferation and angiogenesis have significant potential as chemotherapeutic agents for the treatment of pancreatic adenocarcinomas as well as multiple other malignancies.
Negative_regulation (inhibiting) of EGFR associated with adenocarcinoma
9) Confidence 0.59 Published 2007 Journal Cancer Invest. Section Abstract Doc Link 18027154 Disease Relevance 0.68 Pain Relevance 0.09
EGFR inhibition, whether with antibodies or TKI, causes a cutaneous rash in almost 70% of patients receiving such therapy; generally it involves the face, neck, and upper chest.
Negative_regulation (inhibition) of EGFR in chest associated with exanthema
10) Confidence 0.58 Published 2010 Journal Radiat Oncol Section Body Doc Link PMC2893190 Disease Relevance 0.86 Pain Relevance 0
innovative small molecule tyrosine kinase inhibitor of EGFR with a unique dual-TKI inhibitory activity
Negative_regulation (inhibitor) of EGFR
11) Confidence 0.58 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.57 Pain Relevance 0
Therefore, we hypothesized that lidocaine would suppress the proliferation of cancer cells through the inhibition of EGFR activity.
Negative_regulation (inhibition) of EGFR associated with cancer and lidocaine
12) Confidence 0.58 Published 2006 Journal Anesth. Analg. Section Abstract Doc Link 16551906 Disease Relevance 0.44 Pain Relevance 0.65
The authors hypothesized that lidocaine would suppress tyrosine kinase activity of EGFR and would impair corneal epithelial cell proliferation.
Negative_regulation (suppress) of EGFR in corneal epithelial cell associated with lidocaine
13) Confidence 0.58 Published 2004 Journal Anesthesiology Section Abstract Doc Link 15114219 Disease Relevance 0.07 Pain Relevance 0.47
The Src family of kinases has been implicated in the pathogenesis of head and neck cancer.95,96 In addition, Grandis and colleagues have shown that combined inhibition of the Src and EGFR kinases inhibits HNSCC cell growth and invasion.97 Currently, there is an ongoing phase I study to test the safety of cetuximab and the Src inhibitor dasatinib in patients with advanced malignancies, which will provide more clinical data with regards to the safety of this combination.
Negative_regulation (inhibition) of EGFR in neck associated with head & neck cancer
14) Confidence 0.58 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2921255 Disease Relevance 0.53 Pain Relevance 0
Of these, the epidermal growth factor receptor (EGFR) has been a molecular target of considerable interest and investigation, and there has been a tremendous surge of interest in pursuing targeted therapy of cancers via inhibition of the EGFR.


Negative_regulation (inhibition) of EGFR associated with cancer
15) Confidence 0.57 Published 2005 Journal BMC Cancer Section Abstract Doc Link PMC1266352 Disease Relevance 0.54 Pain Relevance 0
The same downregulation of total EGFR elicited by sulindac sulfide and sulfone was found using this antibody (data not shown), confirming that these results are not peculiar to a single EGFR epitope or a result of an artifact of the use of a single antibody.
Negative_regulation (downregulation) of EGFR
16) Confidence 0.57 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.21 Pain Relevance 0
Further studies are warranted to determine the precise mechanism of EGFR downregulation by sulindac metabolites.
Negative_regulation (downregulation) of EGFR
17) Confidence 0.57 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.24 Pain Relevance 0.09
In addition, inhibition of apoptosis with the broad specificity caspase inhibitor ZVAD did not prevent EGFR downregulation by sulindac metabolites.
Negative_regulation (downregulation) of EGFR associated with apoptosis
18) Confidence 0.57 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.28 Pain Relevance 0.11
Thus, downregulation of EGFR could mediate the apoptotic and chemopreventive effects of NSAIDs and could explain some of the clinical evidence of additive growth inhibitory effects of EGFR inhibitors and NSAIDs.
Negative_regulation (downregulation) of EGFR associated with cinod and apoptosis
19) Confidence 0.57 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.89 Pain Relevance 0.41
Our data demonstrate that EGFR inhibition is not a consequence of caspase activation or due to the apoptotic effects of the drugs in that apoptosis was first detected 24 h after sulindac metabolite treatment, whereas downregulation of EGFR was seen as early as 1 to 12 hours after drug treatment.
Negative_regulation (downregulation) of EGFR associated with apoptosis
20) Confidence 0.57 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.29 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox